secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-07-27T20:10:37+00:00
Accession:  0001193125-26-318078
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Therapeutics appoints Terence Rooney as CMO; Jared Gollob retires
------------------------------------------------------------------------

- Jared Gollob retired as CMO effective July 27, 2026; will remain as advisor through Dec 31, 2026.
- Terence Rooney appointed CMO, previously SVP Portfolio & Asset Management Leader, Immunology at Johnson & Johnson.
- Rooney also held senior immunology R&D roles at Eli Lilly and Roche; contributed to approvals of STELARA, TREMFYA, OLUMIANT.
- Gollob's resignation is for personal reasons and not due to any disagreement with company policies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526318078/0001193125-26-318078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526318078/d167778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-318078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer